Pharsight

Nuvigil patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7132570 CEPHALON Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Dec, 2023

(2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346 CEPHALON Pharmaceutical formulations of modafinil
Nov, 2023

(2 months from now)

US7297346

(Pediatric)

CEPHALON Pharmaceutical formulations of modafinil
May, 2024

(7 months from now)

US7132570

(Pediatric)

CEPHALON Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Jun, 2024

(8 months from now)

Nuvigil is owned by Cephalon.

Nuvigil contains Armodafinil.

Nuvigil has a total of 4 drug patents out of which 0 drug patents have expired.

Nuvigil was authorised for market use on 15 June, 2007.

Nuvigil is available in tablet;oral dosage forms.

The generics of Nuvigil are possible to be released after 18 June, 2024.

Drugs and Companies using ARMODAFINIL ingredient

Market Authorisation Date: 15 June, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of NUVIGIL before it's drug patent expiration?
More Information on Dosage

NUVIGIL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic